Cancer Genomics

Cancer Genomics

Next Generation Sequencing technologies is revolutionizing Personalized Medicine especially in Oncology. From ambiguous tumors to prevalent cancer, advances in sequencing technologies are predicting the right therapy for patients.

Leucine Rich Bio AGIS platform elucidates the right therapy for Cancer Patients. AGIS provides information about cancer-related somatic and germline mutations, curated from published research and calls out the relevant mutations (including substitutions, insertions, deletions, and indels) associated with various cancer types, and provides the resulting data as a report. Our physician tailored reports offers clinically significant analysis of actionable mutations for better Theranostic Value.

Application of NGS in oncology is warranted by the following facts:-
NGS can and is being used to identify germline mutations linked to familial cancer syndrome. Eg. BRCA1/2 for familial breast and ovarian cancer NGS is being used to identify somatic mutations in the genes which are of therapeutic importance in tumors. Eg. Mutations in the B-Raf/MEK pathway in melanoma patients. Melanoma patients who have a V600E BRAF mutation can be prescribed Vemurafinib as a potential targeted therapy.

How does NGS benefit an Oncologist?
There are many ways by which NGS technology can aid an oncologist:

1. Proper Diagnosis
Tumor subtypes that only a few years ago were defined by morphologic criteria are now defined by genetic mutations, either inclusively or exclusively.

2. Appropriate targeted therapy
NGS aids in finding an appropriate “targeted therapy”, as an increasing number of therapies have indications based on DNA sequencing results. Patients who lack the mutation targeted by a drug will not only fail to benefit, but can actually be harmed by inappropriate targeted therapies.

3. Monitoring resistance
Resistance mutations can lead to patients not responding to therapies. For example, resistance to EGFR targeted therapies in cancer very frequently involves a single point mutation, and can possibly be overcome by merely switching to a different agent. NGS allows a more complete overview of tumor dynamics, and is more likely to shed light on idiopathic resistance mechanisms than a single gene assay.

For more information please Get In Touch with us.

call us on
+91-80-4370 1572
working hours
Mon to Fri
09:00am-05:00pm
ask for a free quote
info@leucinerichbio.com